Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Artemis 2 astronauts are now headed to the moon. Why has it taken humanity so long to go back? - 2Happy with Running Shoes for 2024
- 3The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- 4Figure out How to Stay away from Normal Handshaking Missteps
- 5Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- Key Business Regulations to Consider While Arranging Your Independent venture
- NASA funds new tech for upcoming 'Super Hubble' to search for alien life: 'We intend to move with urgency'
- The Leonid meteor shower is peaking early this week. Here’s what to know
- Pick Your #1 Sort Of Espresso
- Investigate Business Mastercard Choices for Better Rewards and Rewards
- An eye for an eye: People agree about the values of body parts across cultures and eras
